Human cell programming company bit.bio closes $25M Series D funding to enhance its cell models and increase technology access. The investment includes support from M&G Investments and Dr Jonathan Milner.
PRIVATENov 04, 2026
Amount Raised
$25 Million
Round Type
Series D
CambridgeshireInformation TechnologyFinancial ServicesSoftwareScience And EngineeringPayments
Investors
Dr. Jonathan MilnerM&G Investments
Description
bit.bio has secured $25 million in Series D funding aimed at expanding its portfolio of human cell models for pharmaceutical companies and research organizations. This round follows an earlier Series C funding and addresses the growing demand for reliable human cell-based alternatives in drug discovery. The company's opti-ox™ platform enables consistent and scalable production of defined human cell types. With over 50 human cell types in its ioCells portfolio, bit.bio is positioned to lead in providing models for various applications in drug discovery and disease research.
Who to call at bit.bio, and when
A new round usually means bit.bio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day bit.bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at bit.bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at bit.bio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
bit.bio
Location
Cambridgeshire, England, United Kingdom
About
bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures.
We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines.
Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies.
To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision.
Collaboration is at the heart of bit.bio. Join us on our journey.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment bit.bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeshireInformation TechnologyFinancial ServicesSoftwareScience And EngineeringPayments